TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity

OncoImmunology

Volumn 2, Issue 12, 2013, Pages

  Cartellieri, Marc ^a   Arndt, Claudia ^a   Feldmann, Anja ^a,b   von Bonin, Malte ^c   Ewen, Eva Maria ^a   Koristka, Stefanie ^a   Michalk, Irene ^a   Stamova, Slava ^a   Berndt, Nicole ^a   Gocht, Anne ^a   Bornhäuser, Martin ^c   Ehninger, Gerhard ^c   Schmitz, Marc ^a,d   Bachmann, Michael ^a,b,d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

Acute myeloid leukemia; CD137; CD33; Co stimulatory ligands; Immunotherapy; Modular targeting system; Single chain bispecific antibodies; T cell retargeting

Indexed keywords

BISPECIFIC ANTIBODY; CD137 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; LA ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR SUPERFAMILY MEMBER 9; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN BINDING CELL; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CD3+ T LYMPHOCYTE; CELL ACTIVATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; HUMAN; PROSTATE CARCINOMA; TUMOR IMMUNITY;

EID: 84896721321     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26770     Document Type: Article

References (10)

1. Arndt C, von Bonin M, Cartellieri M, Feldmann A, Koristka S, Michalk I, Stamova S, Bornhäuser M, Schmitz M, Ehninger G, et al. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia 2013; 27:964-7; PMID:23325142; http://dx.doi. org/10.1038/leu.2013.18
2. Feldmann A, Arndt C, Töpfer K, Stamova S, Krone F, Cartellieri M, Koristka S, Michalk I, Lindemann D, Schmitz M, et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol 2012; 189:3249-59; PMID:22875801; http://dx.doi.org/10.4049/ jimmunol.1200341
3. Stamova S, Cartellieri M, Feldmann A, Bippes CC, Bartsch H, Wehner R, Schmitz M, von Bonin M, Bornhäuser M, Ehninger G, et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia 2011; 25:1053-6; PMID:21415850; http://dx.doi.org/10.1038/ leu.2011.42
4. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-7; PMID:18703743; http://dx.doi. org/10.1126/science.1158545
5. Stamova S, Cartellieri M, Feldmann A, Arndt C, Koristka S, Bartsch H, Bippes CC, Wehner R, Schmitz M, von Bonin M, et al. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Mol Immunol 2011; 49:474-82; PMID:22014687; http:// dx.doi.org/10.1016/j.molimm.2011.09.019
6. Arndt C, Feldmann A, von Bonin M, Cartellieri M, Ewen EM, Koristka S, Michalk I, Stamova S, Berndt N, Gocht A, et al. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia 2013; 10; PMID:23958923; http://dx.doi.org/10.1038/ leu.2013.243
7. Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, Michalk I, Wiefel K, Stamova S, Schmitz M, Ehninger G, et al. Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun 2013; 42:105-16; PMID:23352111; http://dx.doi.org/10.1016/j.jaut.2013.01.002
8. Hornig N, Kermer V, Frey K, Diebolder P, Kontermann RE, Müller D. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. J Immunother 2012; 35:418-29; PMID:22576347; http://dx.doi.org/10.1097/CJI.0b013e3182594387
9. Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, Temme A, Schmitz M. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol 2010; 2010:956304; PMID:20467460; http:// dx.doi.org/10.1155/2010/956304 10.
10. Davila ML, Brentjens R, Wang X, Rivière I, Sadelain M. How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology 2012; 1:1577-83; PMID:23264903; http://dx.doi. org/10.4161/onci.22524